Drug Profile
Isatuximab - ImmunoGen/Sanofi
Alternative Names: Anti-CD38 monoclonal antibody - Sanofi; hu38SB19; Isatuximab-irfc; SAR-650984; SarclisaLatest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Developer Roche; Sanofi
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ADP-ribosyl cyclase inhibitors; Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Natural killer cell stimulants; Regulatory T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple myeloma
- Phase II Acute myeloid leukaemia; Colorectal cancer; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
- Phase I/II Lymphoma; Solid tumours; Urogenital cancer
- Discontinued Autoimmune haemolytic anaemia; Non-small cell lung cancer; Prostate cancer; Renal transplant rejection
Most Recent Events
- 19 Feb 2024 Sanofi announces intention to submit regulatory applications for Multiple myeloma (Combination therapy, Newly diagnosed, First-line therapy) in 2025 (Sanofi pipeline, February 2024)
- 19 Feb 2024 Sanofi announces intention to submit regulatory applications for Multiple Myeloma (Combination therapy, Recurrent, Refractory-metastatic disease, Second-line therapy or greater) in 2025 (Sanofi Pipeline, February 2024)
- 19 Feb 2024 Sanofi announces intention to submit regulatory applications for Multiple myeloma (First-line therapy, Newly diagnosed) in 2024 (Sanofi pipeline, February 2024)